DE2343147C2 - Pyrrolidon-5,5-diphosphonsäuren, deren wasserlösliche Salze, und Verfahren zu ihrer Herstellung - Google Patents
Pyrrolidon-5,5-diphosphonsäuren, deren wasserlösliche Salze, und Verfahren zu ihrer HerstellungInfo
- Publication number
- DE2343147C2 DE2343147C2 DE2343147A DE2343147A DE2343147C2 DE 2343147 C2 DE2343147 C2 DE 2343147C2 DE 2343147 A DE2343147 A DE 2343147A DE 2343147 A DE2343147 A DE 2343147A DE 2343147 C2 DE2343147 C2 DE 2343147C2
- Authority
- DE
- Germany
- Prior art keywords
- acid
- pyrrolidone
- weight
- water
- acids
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- HEJXJRDSBLXLAG-UHFFFAOYSA-N (5-oxo-2-phosphonopyrrolidin-2-yl)phosphonic acid Chemical class OP(O)(=O)C1(P(O)(O)=O)CCC(=O)N1 HEJXJRDSBLXLAG-UHFFFAOYSA-N 0.000 title claims description 18
- 150000003839 salts Chemical class 0.000 title description 15
- 238000000034 method Methods 0.000 title description 8
- 238000002360 preparation method Methods 0.000 title description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 53
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 42
- 239000000243 solution Substances 0.000 description 27
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 21
- 239000000126 substance Substances 0.000 description 20
- 235000019441 ethanol Nutrition 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 18
- 239000002253 acid Substances 0.000 description 14
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 12
- 150000001875 compounds Chemical class 0.000 description 11
- 239000011574 phosphorus Substances 0.000 description 11
- 229910052698 phosphorus Inorganic materials 0.000 description 11
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 10
- 150000007513 acids Chemical class 0.000 description 10
- 239000011575 calcium Substances 0.000 description 10
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 9
- 150000001768 cations Chemical class 0.000 description 9
- 239000011734 sodium Substances 0.000 description 9
- 239000008139 complexing agent Substances 0.000 description 8
- 238000001035 drying Methods 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 229910052708 sodium Inorganic materials 0.000 description 8
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Inorganic materials [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 7
- ZOMBKNNSYQHRCA-UHFFFAOYSA-J calcium sulfate hemihydrate Chemical compound O.[Ca+2].[Ca+2].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O ZOMBKNNSYQHRCA-UHFFFAOYSA-J 0.000 description 7
- 125000004432 carbon atom Chemical group C* 0.000 description 7
- 239000011507 gypsum plaster Substances 0.000 description 7
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 6
- 150000003863 ammonium salts Chemical class 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 229910052791 calcium Inorganic materials 0.000 description 6
- 150000003009 phosphonic acids Chemical class 0.000 description 6
- 239000011591 potassium Substances 0.000 description 6
- 229910052700 potassium Inorganic materials 0.000 description 6
- ISIJQEHRDSCQIU-UHFFFAOYSA-N tert-butyl 2,7-diazaspiro[4.5]decane-7-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCCC11CNCC1 ISIJQEHRDSCQIU-UHFFFAOYSA-N 0.000 description 6
- 229910052586 apatite Inorganic materials 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 239000007795 chemical reaction product Substances 0.000 description 5
- VSIIXMUUUJUKCM-UHFFFAOYSA-D pentacalcium;fluoride;triphosphate Chemical compound [F-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O VSIIXMUUUJUKCM-UHFFFAOYSA-D 0.000 description 5
- 238000001556 precipitation Methods 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- 208000004434 Calcinosis Diseases 0.000 description 4
- 208000006558 Dental Calculus Diseases 0.000 description 4
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 4
- 210000000709 aorta Anatomy 0.000 description 4
- 238000002425 crystallisation Methods 0.000 description 4
- 230000008025 crystallization Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 4
- 238000002329 infrared spectrum Methods 0.000 description 4
- 150000004682 monohydrates Chemical class 0.000 description 4
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 4
- YPPQYORGOMWNMX-UHFFFAOYSA-L sodium phosphonate pentahydrate Chemical compound [Na+].[Na+].[O-]P([O-])=O YPPQYORGOMWNMX-UHFFFAOYSA-L 0.000 description 4
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 4
- IAHFWCOBPZCAEA-UHFFFAOYSA-N succinonitrile Chemical compound N#CCCC#N IAHFWCOBPZCAEA-UHFFFAOYSA-N 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 4
- AFDOVWBBOLLVHJ-UHFFFAOYSA-N (1-ethyl-5-oxo-2-phosphonopyrrolidin-2-yl)phosphonic acid Chemical compound CCN1C(=O)CCC1(P(O)(O)=O)P(O)(O)=O AFDOVWBBOLLVHJ-UHFFFAOYSA-N 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- RHQQHZQUAMFINJ-GKWSUJDHSA-N 1-[(3s,5s,8s,9s,10s,11s,13s,14s,17s)-3,11-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-hydroxyethanone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CC[C@H]21 RHQQHZQUAMFINJ-GKWSUJDHSA-N 0.000 description 3
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- SNCZNSNPXMPCGN-UHFFFAOYSA-N butanediamide Chemical compound NC(=O)CCC(N)=O SNCZNSNPXMPCGN-UHFFFAOYSA-N 0.000 description 3
- 230000002308 calcification Effects 0.000 description 3
- 229910001424 calcium ion Inorganic materials 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000000354 decomposition reaction Methods 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 239000010440 gypsum Substances 0.000 description 3
- 229910052602 gypsum Inorganic materials 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000004448 titration Methods 0.000 description 3
- 235000005282 vitamin D3 Nutrition 0.000 description 3
- 239000011647 vitamin D3 Substances 0.000 description 3
- 229940021056 vitamin d3 Drugs 0.000 description 3
- 239000000341 volatile oil Substances 0.000 description 3
- PSJKMWOFTYGXGF-UHFFFAOYSA-N (1-methyl-5-oxo-2-phosphonopyrrolidin-2-yl)phosphonic acid Chemical compound CN1C(=O)CCC1(P(O)(O)=O)P(O)(O)=O PSJKMWOFTYGXGF-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 238000005904 alkaline hydrolysis reaction Methods 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- HQABUPZFAYXKJW-UHFFFAOYSA-N butan-1-amine Chemical compound CCCCN HQABUPZFAYXKJW-UHFFFAOYSA-N 0.000 description 2
- 159000000007 calcium salts Chemical class 0.000 description 2
- 238000010668 complexation reaction Methods 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 150000001990 dicarboxylic acid derivatives Chemical class 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000012442 inert solvent Substances 0.000 description 2
- 229910003002 lithium salt Inorganic materials 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 229910021645 metal ion Inorganic materials 0.000 description 2
- 239000002324 mouth wash Substances 0.000 description 2
- 229940051866 mouthwash Drugs 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- XUYJLQHKOGNDPB-UHFFFAOYSA-N phosphonoacetic acid Chemical compound OC(=O)CP(O)(O)=O XUYJLQHKOGNDPB-UHFFFAOYSA-N 0.000 description 2
- -1 phosphorus compound Chemical class 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000003352 sequestering agent Substances 0.000 description 2
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- JDVPQXZIJDEHAN-UHFFFAOYSA-N succinamic acid Chemical class NC(=O)CCC(O)=O JDVPQXZIJDEHAN-UHFFFAOYSA-N 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical class OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 150000003443 succinic acid derivatives Chemical class 0.000 description 2
- 229960002317 succinimide Drugs 0.000 description 2
- 239000000606 toothpaste Substances 0.000 description 2
- IIQMHCALCOZBQF-UHFFFAOYSA-N (1-butyl-5-oxo-2-phosphonopyrrolidin-2-yl)phosphonic acid Chemical compound CCCCN1C(=O)CCC1(P(O)(O)=O)P(O)(O)=O IIQMHCALCOZBQF-UHFFFAOYSA-N 0.000 description 1
- KMDMOMDSEVTJTI-UHFFFAOYSA-N 2-phosphonobutanedioic acid Chemical compound OC(=O)CC(C(O)=O)P(O)(O)=O KMDMOMDSEVTJTI-UHFFFAOYSA-N 0.000 description 1
- KFZXVMNBUMVKLN-UHFFFAOYSA-N 4-chloro-5-methyl-2-propan-2-ylphenol Chemical compound CC(C)C1=CC(Cl)=C(C)C=C1O KFZXVMNBUMVKLN-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 206010070918 Bone deformity Diseases 0.000 description 1
- 101100283604 Caenorhabditis elegans pigk-1 gene Proteins 0.000 description 1
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000015924 Lithiasis Diseases 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 201000002481 Myositis Diseases 0.000 description 1
- PHSPJQZRQAJPPF-UHFFFAOYSA-N N-alpha-Methylhistamine Chemical compound CNCCC1=CN=CN1 PHSPJQZRQAJPPF-UHFFFAOYSA-N 0.000 description 1
- 206010029240 Neuritis Diseases 0.000 description 1
- 208000010191 Osteitis Deformans Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 208000027868 Paget disease Diseases 0.000 description 1
- 239000005819 Potassium phosphonate Substances 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- 208000003217 Tetany Diseases 0.000 description 1
- 235000011941 Tilia x europaea Nutrition 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- FRCICXIVPRNPLM-UHFFFAOYSA-N [amino(phosphono)methyl]phosphonic acid Chemical compound OP(=O)(O)C(N)P(O)(O)=O FRCICXIVPRNPLM-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 229910001420 alkaline earth metal ion Inorganic materials 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 239000003674 animal food additive Substances 0.000 description 1
- 230000002547 anomalous effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229940043430 calcium compound Drugs 0.000 description 1
- 150000001674 calcium compounds Chemical class 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000008280 chlorinated hydrocarbons Chemical class 0.000 description 1
- 229940031956 chlorothymol Drugs 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- YXXXKCDYKKSZHL-UHFFFAOYSA-M dipotassium;dioxido(oxo)phosphanium Chemical compound [K+].[K+].[O-][P+]([O-])=O YXXXKCDYKKSZHL-UHFFFAOYSA-M 0.000 description 1
- 238000005048 flame photometry Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000004571 lime Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- GVALZJMUIHGIMD-UHFFFAOYSA-H magnesium phosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GVALZJMUIHGIMD-UHFFFAOYSA-H 0.000 description 1
- 239000004137 magnesium phosphate Substances 0.000 description 1
- 229910000157 magnesium phosphate Inorganic materials 0.000 description 1
- 229960002261 magnesium phosphate Drugs 0.000 description 1
- 235000010994 magnesium phosphates Nutrition 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 208000027202 mammary Paget disease Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- MBKDYNNUVRNNRF-UHFFFAOYSA-N medronic acid Chemical compound OP(O)(=O)CP(O)(O)=O MBKDYNNUVRNNRF-UHFFFAOYSA-N 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- HJZKOAYDRQLPME-UHFFFAOYSA-N oxidronic acid Chemical compound OP(=O)(O)C(O)P(O)(O)=O HJZKOAYDRQLPME-UHFFFAOYSA-N 0.000 description 1
- 229960004230 oxidronic acid Drugs 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 239000010451 perlite Substances 0.000 description 1
- 235000019362 perlite Nutrition 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000003018 phosphorus compounds Chemical class 0.000 description 1
- FAIAAWCVCHQXDN-UHFFFAOYSA-N phosphorus trichloride Chemical compound ClP(Cl)Cl FAIAAWCVCHQXDN-UHFFFAOYSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229940034610 toothpaste Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-O triethanolammonium Chemical class OCC[NH+](CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-O 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- LRXTYHSAJDENHV-UHFFFAOYSA-H zinc phosphate Chemical compound [Zn+2].[Zn+2].[Zn+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O LRXTYHSAJDENHV-UHFFFAOYSA-H 0.000 description 1
- 229910000165 zinc phosphate Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
- A61K8/4913—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/55—Phosphorus compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
- C07F9/3839—Polyphosphonic acids
- C07F9/3873—Polyphosphonic acids containing nitrogen substituent, e.g. N.....H or N-hydrocarbon group which can be substituted by halogen or nitro(so), N.....O, N.....S, N.....C(=X)- (X =O, S), N.....N, N...C(=X)...N (X =O, S)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/572—Five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/51—Chelating agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/06—Chelate
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Curing Cements, Concrete, And Artificial Stone (AREA)
Priority Applications (22)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE2343147A DE2343147C2 (de) | 1973-08-27 | 1973-08-27 | Pyrrolidon-5,5-diphosphonsäuren, deren wasserlösliche Salze, und Verfahren zu ihrer Herstellung |
| DK411674A DK138695C (da) | 1973-08-27 | 1974-08-01 | Fremgangsmaade til fremstilling af pyrrolidon-5,5-difosfonsyrer og vandoploeselige salte heraf |
| NLAANVRAGE7410367,A NL180512C (nl) | 1973-08-27 | 1974-08-01 | Werkwijze ter bereiding van pyrrolidon-5,5-difosfonzuren en zouten daarvan. |
| US05/498,997 US3960888A (en) | 1973-08-27 | 1974-08-20 | Pyrrolidone-5,5-diphosphonic acids |
| IT26457/74A IT1020065B (it) | 1973-08-27 | 1974-08-21 | Acido pirrolidon 5.5 difosfonico |
| GB3706374A GB1452027A (en) | 1973-08-27 | 1974-08-23 | Pyroolidon-5,5-diphosphonic acids |
| IE1777/74A IE41323B1 (en) | 1973-08-27 | 1974-08-26 | Pyrrolidon-5,5-diphosphonec acids |
| CH278978A CH608504A5 (enExample) | 1973-08-27 | 1974-08-26 | |
| AT689474A AT326686B (de) | 1973-08-27 | 1974-08-26 | Verfahren zur herstellung von neuen diphosphonsäuren |
| CA207,803A CA1027576A (en) | 1973-08-27 | 1974-08-26 | Pyrrolidone-5,5-diphosphonic acids |
| LU70793A LU70793A1 (enExample) | 1973-08-27 | 1974-08-26 | |
| MX531674U MX4871E (es) | 1973-08-27 | 1974-08-26 | Procedimiento para preparar acidos difosfonicos |
| BR7078/74A BR7407078D0 (pt) | 1973-08-27 | 1974-08-26 | Processo para a fabricacao de acidos pirrolidono-5 5 difosfonicos |
| CH1160174A CH608503A5 (enExample) | 1973-08-27 | 1974-08-26 | |
| AT912174*7A AT327949B (de) | 1973-08-27 | 1974-08-26 | Verfahren zur herstellung von neuen diphosphonsauren |
| BE147906A BE819187A (fr) | 1973-08-27 | 1974-08-26 | Nouveaux acides pyrrolidone-5,5-diphosphoniques et leur procede de preparation |
| FR7429202A FR2245370B1 (enExample) | 1973-08-27 | 1974-08-27 | |
| JP9831974A JPS5710877B2 (enExample) | 1973-08-27 | 1974-08-27 | |
| AT912074A AT332554B (de) | 1973-08-27 | 1974-11-14 | Mund- und zahnpflegemittel |
| US05/659,926 US4034086A (en) | 1973-08-27 | 1976-02-20 | Pyrrolidone-5,5-diphosphonic acids |
| DK256877A DK139100C (da) | 1973-08-27 | 1977-06-09 | Fremgangsmaade til fremstilling af pyrrolidon-5,5-difosfonsyrer |
| CA290,283A CA1043341A (en) | 1973-08-27 | 1977-11-07 | Process for preparing pyrrolidone-5,5-diphosphonic acids |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE2343147A DE2343147C2 (de) | 1973-08-27 | 1973-08-27 | Pyrrolidon-5,5-diphosphonsäuren, deren wasserlösliche Salze, und Verfahren zu ihrer Herstellung |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE2343147A1 DE2343147A1 (de) | 1975-04-03 |
| DE2343147C2 true DE2343147C2 (de) | 1982-06-09 |
Family
ID=5890807
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE2343147A Expired DE2343147C2 (de) | 1973-08-27 | 1973-08-27 | Pyrrolidon-5,5-diphosphonsäuren, deren wasserlösliche Salze, und Verfahren zu ihrer Herstellung |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US3960888A (enExample) |
| JP (1) | JPS5710877B2 (enExample) |
| AT (2) | AT326686B (enExample) |
| BE (1) | BE819187A (enExample) |
| BR (1) | BR7407078D0 (enExample) |
| CA (1) | CA1027576A (enExample) |
| CH (2) | CH608504A5 (enExample) |
| DE (1) | DE2343147C2 (enExample) |
| DK (1) | DK138695C (enExample) |
| FR (1) | FR2245370B1 (enExample) |
| GB (1) | GB1452027A (enExample) |
| IE (1) | IE41323B1 (enExample) |
| IT (1) | IT1020065B (enExample) |
| LU (1) | LU70793A1 (enExample) |
| NL (1) | NL180512C (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2745084A1 (de) * | 1977-10-07 | 1979-04-12 | Henkel Kgaa | Diphosphonsaeuren |
| DE3027040A1 (de) * | 1980-07-17 | 1982-02-25 | Hoechst Ag, 6000 Frankfurt | Dimethylphosphinyl-alkanphosphonsaeuren, ein verfahren zu ihrer herstellung und ihre verwendung als gipsabbindeverzoegerer |
| US4569838A (en) * | 1983-12-23 | 1986-02-11 | Colgate-Palmolive Company | Dentifrice |
| GB2157279A (en) * | 1984-04-12 | 1985-10-23 | Dow Chemical Co | Well treating composition |
| US4575456A (en) * | 1984-11-30 | 1986-03-11 | Colgate-Palmolive Company | Gel dentifrice of desirable consistency |
| US5104863A (en) * | 1984-12-21 | 1992-04-14 | The Procter & Gamble Company | Certain bicycloalkane and azabicycloalkane-1,1-diphosphonic acid derivatives useful for treating diseases associated with abnormal calcium and phosphate metabolism |
| IL77243A (en) * | 1984-12-21 | 1996-11-14 | Procter & Gamble | Pharmaceutical compositions containing geminal diphosphonic acid compounds and certain such novel compounds |
| US4687768A (en) * | 1984-12-21 | 1987-08-18 | The Procter & Gamble Company | Certain hexahydroindan-2,2-diphosphonic acids useful in treating diseases associated with abnormal calcium and phosphate metabolism |
| JPS62185092A (ja) * | 1986-02-07 | 1987-08-13 | Teijin Ltd | 新規ホスホン酸誘導体および除草剤 |
| US4868164A (en) * | 1986-12-19 | 1989-09-19 | Norwich Eaton Pharmaceuticals, Inc. | Octahydro-pyridine diphosphonate compounds, pharmaceutical compositions, and methods for treating abnormal calcium and phosphate metabolism |
| US5071840A (en) * | 1986-12-19 | 1991-12-10 | Norwich Eaton Pharmaceuticals, Inc. | Certain heterocyclic substituted diphosphonate compounds pharmaceutical compositions, and methods of treating abnormal calcium and phosphate metabolism |
| IL86951A (en) * | 1987-07-06 | 1996-07-23 | Procter & Gamble Pharma | Methylene phosphonoalkylphosphinates and pharmaceutical preparations containing them |
| US4966762A (en) * | 1988-10-06 | 1990-10-30 | Fmc Corporation | Process for manufacturing a soda ash peroxygen carrier |
| US4970058A (en) * | 1988-10-06 | 1990-11-13 | Fmc Corporation | Soda ash peroxygen carrier |
| US5045296A (en) * | 1989-10-30 | 1991-09-03 | Fmc Corporation | Sodium carbonate perhydrate process |
| GB9021393D0 (en) * | 1990-10-02 | 1990-11-14 | Interox Chemicals Ltd | Peroxide compositions |
| US5318772A (en) * | 1991-12-10 | 1994-06-07 | The Dow Chemical Company | Oral compositions for inhibiting calculus formation |
| DE69328903T2 (de) * | 1992-12-16 | 2000-12-07 | Colgate-Palmolive Co., New York | Gegen zahnbelag, gingivitis und karies wirkende orale zusammensetzung |
| US6905672B2 (en) * | 1999-12-08 | 2005-06-14 | The Procter & Gamble Company | Compositions and methods to inhibit tartar and microbes using denture adhesive compositions with colorants |
| US6475497B1 (en) | 1999-12-08 | 2002-11-05 | The Procter & Gamble Company | Tartar control denture adhesive compositions |
| US6475498B1 (en) | 1999-12-08 | 2002-11-05 | The Procter & Gamble Company | Method to inhibit tartar and stain using denture adhesive compositions |
| US6677391B1 (en) | 1999-12-08 | 2004-01-13 | The Procter & Gamble Company | Tartar control denture adhesive compositions |
| US6409824B1 (en) | 2000-04-25 | 2002-06-25 | United States Gypsum Company | Gypsum compositions with enhanced resistance to permanent deformation |
| EP1450844A4 (en) * | 2001-11-09 | 2009-07-29 | Enzon Inc | POLYMER THIOL-LINKED PRODRUGS USING BENZYL ELIMINATION SYSTEMS |
| US20050118130A1 (en) * | 2003-06-20 | 2005-06-02 | Ferdinand Utz | Hydrocolloids and process therefor |
| US20050129643A1 (en) * | 2003-06-20 | 2005-06-16 | Lepilleur Carole A. | Hydrocolloids and process therefor |
| US8450294B2 (en) * | 2004-12-16 | 2013-05-28 | Lubrizol Advanced Materials, Inc. | Shampoo compositions |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2706194A (en) * | 1951-05-14 | 1955-04-12 | Shell Dev | Esters of phosphonic acids |
| US2644002A (en) * | 1951-08-29 | 1953-06-30 | American Cyanamid Co | Thiophosphatosuccinimides |
| BE547771A (enExample) * | 1955-05-13 | |||
| US2865912A (en) * | 1956-06-05 | 1958-12-23 | Basf Ag | Process for the production of o.o-dialkylphosphoric or o.o-dialkylthionophosphoric acid esters of n-alkylol lactams |
| US2844582A (en) * | 1956-07-17 | 1958-07-22 | Jr Charles F Raley | Heterocyclic aryl phosphorus esters |
| FR1439192A (fr) * | 1965-04-07 | 1966-05-20 | Rhone Poulenc Sa | Procédé de préparation d'alpha-pyrrolidones nu-substituées |
| DE1958123C3 (de) * | 1969-11-19 | 1978-09-28 | Henkel Kgaa, 4000 Duesseldorf | Verfahren zur Herstellung von 1 -Aminoalkan-1,1 -diphosphonsäuren oder deren Salzen |
-
1973
- 1973-08-27 DE DE2343147A patent/DE2343147C2/de not_active Expired
-
1974
- 1974-08-01 NL NLAANVRAGE7410367,A patent/NL180512C/xx not_active IP Right Cessation
- 1974-08-01 DK DK411674A patent/DK138695C/da not_active IP Right Cessation
- 1974-08-20 US US05/498,997 patent/US3960888A/en not_active Expired - Lifetime
- 1974-08-21 IT IT26457/74A patent/IT1020065B/it active
- 1974-08-23 GB GB3706374A patent/GB1452027A/en not_active Expired
- 1974-08-26 CH CH278978A patent/CH608504A5/xx not_active IP Right Cessation
- 1974-08-26 CA CA207,803A patent/CA1027576A/en not_active Expired
- 1974-08-26 CH CH1160174A patent/CH608503A5/xx not_active IP Right Cessation
- 1974-08-26 BE BE147906A patent/BE819187A/xx not_active IP Right Cessation
- 1974-08-26 IE IE1777/74A patent/IE41323B1/xx unknown
- 1974-08-26 AT AT689474A patent/AT326686B/de not_active IP Right Cessation
- 1974-08-26 AT AT912174*7A patent/AT327949B/de not_active IP Right Cessation
- 1974-08-26 LU LU70793A patent/LU70793A1/xx unknown
- 1974-08-26 BR BR7078/74A patent/BR7407078D0/pt unknown
- 1974-08-27 FR FR7429202A patent/FR2245370B1/fr not_active Expired
- 1974-08-27 JP JP9831974A patent/JPS5710877B2/ja not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| US3960888A (en) | 1976-06-01 |
| CA1027576A (en) | 1978-03-07 |
| AT327949B (de) | 1976-02-25 |
| ATA689474A (de) | 1975-03-15 |
| NL180512C (nl) | 1987-03-02 |
| DK138695B (da) | 1978-10-16 |
| FR2245370A1 (enExample) | 1975-04-25 |
| JPS5710877B2 (enExample) | 1982-03-01 |
| CH608504A5 (enExample) | 1979-01-15 |
| BE819187A (fr) | 1975-02-26 |
| BR7407078D0 (pt) | 1975-06-24 |
| AT326686B (de) | 1975-12-29 |
| IE41323L (en) | 1975-02-27 |
| IE41323B1 (en) | 1979-12-05 |
| LU70793A1 (enExample) | 1975-06-11 |
| ATA912174A (de) | 1975-05-15 |
| DK138695C (da) | 1979-03-26 |
| DK411674A (enExample) | 1975-04-28 |
| FR2245370B1 (enExample) | 1978-07-21 |
| DE2343147A1 (de) | 1975-04-03 |
| GB1452027A (en) | 1976-10-06 |
| IT1020065B (it) | 1977-12-20 |
| CH608503A5 (enExample) | 1979-01-15 |
| NL7410367A (nl) | 1975-03-03 |
| JPS5050365A (enExample) | 1975-05-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE2343147C2 (de) | Pyrrolidon-5,5-diphosphonsäuren, deren wasserlösliche Salze, und Verfahren zu ihrer Herstellung | |
| DE2343196C3 (de) | Aiacycloalkan-2^-diphosphonsäuren oder deren wasserlösliche Salze | |
| DE2343195C2 (de) | Cyclische Aminophosphonsäuren und Verfahren zu deren Herstellung | |
| US3988443A (en) | Azacycloalkane-2,2-diphosphonic acids | |
| DE2745083C2 (de) | Hydroxydiphosphonsäuren und Verfahren zu deren Herstellung | |
| DE2534391C2 (de) | 1-Hydroxy-3-aminoalkan-1,1-diphosphonsäuren | |
| DE2405254C2 (de) | Verwendung von 3-Amino-1-Hydroxypropan-1, 1-diphosphonsäure oder ihrer wasserlöslichen Salze bei der Beeinflußung von Calciumstoffwechselstörungen im menschlichen oder tierischen Körper | |
| EP0252505B1 (de) | 1-Hydroxy-3-(N-methyl-N-propylamino)propan-1,1-diphosphonsäure; Verfahren zu dessen Herstellung und diese Verbindung enthaltende Arzneimittel | |
| US4034086A (en) | Pyrrolidone-5,5-diphosphonic acids | |
| EP0175315A2 (de) | 4-Dimethylamino-1-hydroxybutan-1,1-diphosphonsäure, deren wasserlösliche Salze, Verfahren zu ihrer Herstellung sowie ihre Verwendung | |
| DE2360797A1 (de) | Pharmazeutische praeparate | |
| DE2534390C2 (de) | 1,3-Di-aminoalkan-1,1-diphosphonsäuren | |
| DE3805663A1 (de) | Oxaalkanpolyphosphonsaeuren, ihre verwendung als thresholder sowie diese verbindungen enthaltende, komplexierend wirkende zusammensetzungen | |
| DE69624707T2 (de) | Therapeutische verwendung von 1-amino-3-(n,n-dimethylamino)-propyliden-1,1-bisphosphonsäure und ihre salze | |
| DE2343197A1 (de) | Pharmazeutische oder kosmetische praeparate | |
| DE2602030C2 (de) | Diphosphonoalkancarbonsäuren und Verfahren zu deren Herstellung | |
| DE69523914T2 (de) | Pyridylbisphosphonate als therapeutische wirkstoffe | |
| DE2513966C2 (de) | Piperidon-6,6-diphosphonsäure und Verfahren zu deren Herstellung | |
| US3984543A (en) | Therapeutic methods employing cyclic aminophosphonic acids | |
| DE2360798A1 (de) | Pharmazeutische oder kosmetische praeparate | |
| DE2745084C2 (enExample) | ||
| DE2360711A1 (de) | Pharmazeutische praeparate | |
| DE2343146A1 (de) | Pharmazeutische oder kosmetische praeparate | |
| DE2360719A1 (de) | Pharmazeutische oder kosmetische praeparate | |
| DE3313049A1 (de) | Pharmakologisch wirksame biphosphonate, verfahren fuer ihre herstellung und diese enthaltende pharmazeutische zusammensetzungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| OD | Request for examination | ||
| D2 | Grant after examination | ||
| 8339 | Ceased/non-payment of the annual fee |